Patients with treatment-resistant depression, anxiety, and PTSD are often desperate. When conventional medications fail or cause intolerable side effects, the internet offers an alternative: peptides. Semax and Selank from Russia. Oxytocin nasal spray. BPC-157 for gut-brain healing. These compounds are discussed in online forums with enthusiasm that far outpaces the evidence.
This article reviews what is actually known about peptides in mental health. It is not optimistic. The evidence base is thin, geographically narrow, and methodologically weak. But it is worth understanding exactly why, so that patients can make informed decisions and clinicians can address questions with accuracy rather than dismissal.
Semax: Russian origins and Western absence
Semax is a synthetic heptapeptide derived from ACTH(4-10), developed in the Soviet Union during the 1980s for cerebrovascular disorders. In Russia, it is approved as a nasal spray for cognitive recovery after stroke and for optic nerve neuropathy. The proposed mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and modulation of serotonergic signaling.
The BDNF hypothesis is attractive. Low BDNF is associated with depression, and antidepressants like SSRIs increase BDNF expression in animal models. If Semax upregulates BDNF, it might have antidepressant properties. But this chain of reasoning has gaps. First, BDNF upregulation has been shown in rodent brains and limited human biomarker studies, not in clinical trials with psychiatric endpoints. Second, BDNF is not the only pathway in depression. Third, the majority of Semax studies are published in Russian-language journals not indexed in PubMed.
A 2018 review by Gusev and colleagues summarized the Russian literature, noting improvements in attention and memory in small clinical samples (Gusev et al., Zh Nevrol Psikhiatr 2018). No Phase III randomized trial of Semax for depression or anxiety has been published in an English-language, PubMed-indexed journal. The drug is not approved by the FDA, EMA, or any Western regulatory agency for any indication.
Selank: anxiolytic claims without replication
Selank was developed alongside Semax and shares its Soviet origin. It is marketed in Russia and some former Soviet states as an anxiolytic nasal spray. The mechanism is attributed to modulation of GABA-A receptor subunit expression and inhibition of enkephalin-degrading enzymes.
Russian clinical reports describe reduced anxiety in generalized anxiety disorder patients. These studies are small, typically 30 to 60 participants, and lack the methodological rigor of modern CONSORT-compliant trials. There is no blinding described in most reports. Control groups are often absent or receive no intervention rather than placebo. The studies have not been replicated by independent Western research groups.
Claims that Selank is 'as effective as benzodiazepines without addiction' are unsupported by head-to-head randomized trials. No published study has compared Selank to lorazepam, diazepam, or even placebo using standardized psychiatric rating scales in a Western trial registry. The absence of abuse liability is plausible given its non-benzodiazepine mechanism, but absence of evidence is not evidence of absence.
Oxytocin: context is everything
Oxytocin is the best-characterized peptide in this group. It is a nonapeptide with established physiological roles in parturition, lactation, and social bonding. Intranasal oxytocin has been studied in dozens of trials for social anxiety, autism spectrum disorder, and PTSD fear extinction.
The results are inconsistent. A 2013 meta-analysis by Macdonald and Feifel found that oxytocin reduced anxiety in some experimental paradigms but increased in-group favoritism and envy in others (PMID: 23709397). Neuroimaging studies show reduced amygdala reactivity to social threat in some participants but not others. The effect varies by attachment style, sex, baseline oxytocin levels, and social context.
This context-dependency means oxytocin is not a universal anxiolytic. It is a social modulator. For a patient with secure attachment in a supportive environment, it might reduce social vigilance. For a patient with anxious attachment in a competitive environment, it might heighten sensitivity to rejection. There is no FDA-approved oxytocin formulation for anxiety or depression, and compounding pharmacy products vary widely in concentration and stability.
BPC-157 and the gut-brain axis: animal data only
BPC-157 is frequently promoted for depression and anxiety based on the gut-brain axis hypothesis. The reasoning goes like this: gut inflammation contributes to depression, BPC-157 heals the gut in rodents, therefore BPC-157 might help depression. Each link in this chain is weak.
In rodents, BPC-157 does show interesting pharmacology. It protects against serotonin syndrome induced by high-dose SSRIs plus MAOIs. It modulates dopaminergic pathways in brain injury models. It accelerates gastric ulcer healing. These are pharmacological curiosities, not clinical evidence. No human clinical trial has tested BPC-157 for depression, anxiety, PTSD, or any psychiatric indication. Extrapolating from rodent gut-brain data to human mental health treatment is not evidence-based practice. It is hope-based speculation.
What does not work
Several peptides are promoted for mood enhancement despite absent or negative evidence:
- Melanotan II: Marketed for tanning and sexual arousal. No credible evidence for antidepressant effects. Side effects include nausea, facial flushing, and melanoma risk.
- GH-releasing peptides (CJC-1295, ipamorelin): No published trials for depression or anxiety. Any mood benefit from improved sleep is indirect and unstudied.
- Thymosin beta-4 (TB-500): No psychiatric indications or trials. WADA-banned in competitive sport.
- Dihexa: Promoted as a cognitive enhancer with no published human trials for any indication.
Drug interactions: the hidden danger
Peptides are biologically active compounds. They can interact with psychiatric medications through mechanisms that are poorly studied but clinically relevant.
- SSRIs plus Semax or Selank: Both affect serotonergic tone. The risk of serotonin syndrome is theoretical but not zero. No interaction studies exist.
- Benzodiazepines plus Selank: Additive GABAergic effects are possible. Tapering benzodiazepines requires medical supervision regardless of peptide use.
- Stimulants plus Semax: Both influence catecholaminergic pathways. Cardiovascular and anxiety effects may be additive.
- Lithium plus any new peptide: Lithium has a narrow therapeutic window. Introducing unstudied compounds in a patient on lithium is high-risk.
- MAOIs plus vasoactive peptides: Potential hypertensive interactions. MAOI dietary restrictions are already burdensome; adding peptide unknowns is unwise.
The placebo problem
Online forums contain detailed self-experimentation reports. A widely cited Reddit user documented a 30-day stack of Semax, Selank, and BPC-157 for depression, reporting improved mood and motivation. These reports are valuable for generating hypotheses, but they lack controls, blinding, and objective outcomes.
The placebo effect in depression is substantial. Meta-analyses of antidepressant trials show response rates of 30 to 40% for placebo across dozens of studies (PMID: 18303940). Subjective self-reports cannot distinguish pharmacological effects from placebo, regression to the mean, lifestyle changes, or the natural course of a fluctuating condition. Anecdotes are starting points for research, not endpoints for clinical decision-making.
When to see a psychiatrist first
Peptide experimentation should not precede psychiatric evaluation for moderate-to-severe symptoms. The following are indications for prompt professional evaluation:
- Suicidal ideation or self-harm thoughts
- Inability to work or maintain relationships due to mood symptoms
- Psychotic features including hallucinations, delusions, or severe paranoia
- Substance use co-occurring with mood symptoms
- Bipolar disorder or family history of mania. Stimulatory peptides may trigger manic episodes.
What the evidence actually says
The evidence for peptides in anxiety, PTSD, and depression is weak. Semax and Selank have small Russian trials with methodological limitations. Oxytocin has mixed Western data with strong context-dependency. BPC-157 has no human psychiatric data at all. No peptide has FDA approval for any mental health indication.
For patients with treatment-resistant conditions, established options remain more promising. Transcranial magnetic stimulation, ketamine infusion therapy, and electroconvulsive therapy have larger evidence bases and clearer regulatory pathways. Peptides may eventually find a role in psychiatry, but that role will require the same rigorous clinical trials that every other psychiatric medication has undergone. The field is not there yet.